chrismeduri Profile Banner
Chris Meduri, MD MPH Profile
Chris Meduri, MD MPH

@chrismeduri

Followers
1K
Following
2K
Media
26
Statuses
204

Husband to @audrameduri. Father. Traveler. Interventional Cardiologist at Karolinska & Chief Medical Officer of @anteristech #TAVR #TMVR #TreatTR

Stockholm
Joined March 2010
Don't wanna be here? Send us removal request.
@mirvatalasnag
MIЯVΛƬ #IC ༄ 。°
1 year
#NYValves2024 @crfheart @JoaoLCavalcante presents the First in Human #DurAVR results ❓Why another BEV? Unique Flow displacement characteristics & promising early imaging data 🔹20 point biomimetic improvement in LV mass LV remodeling & restoration of laminar flow hence Ao
3
16
43
@CN_publishing
Cardiovascular News
1 year
Insights of FIH and EFS use of DurAVR (@AnterisTech) a single-leaflet design biomimetic valve are presented at #EuroPCR by Chris Meduri
1
2
7
@CN_publishing
Cardiovascular News
2 years
#PCRLV: @azeemlatib presents insights from the first in man implant of the DurAVR biomimetic TAVI valve (@AnterisTech). He reports that the device had a favourable safety profile, and “outstanding” haemodynamic performance
0
7
16
@AndreaScotti21
Andrea Scotti
2 years
⭐️ FIH & EFS data on DurAVR just presented by @azeemlatib #PCRLV 🎯Balloon-expandable 🎯Commissure-alignment 🎯Long coaptation length 🎯EXCELLENT Hemodynamics @chrismeduri @AnterisTech @MonteHeart
2
12
45
@chrismeduri
Chris Meduri, MD MPH
2 years
Visionary work led by @HEARTinMagnet looking at the impact of aortic flow abnormalities on CV disease. Likely an important feature in future AVR development. @JoaoLCavalcante @hahn_rt @J_Sathananthan @sellers_steph
@NatRevCardiol
Nature Reviews Cardiology
2 years
Check out our latest Perspectives article on the link between aortic flow-related abnormalities and cardiovascular disease by Pankaj Garg and colleagues | https://t.co/k0QxCFzoUF
0
0
8
@CEOPaterson
Wayne Paterson
2 years
Great week at TCT with incredible data being presented by Anteris demonstrating superior MPG's ,superior EOA's and superior DVI's to current therapies. A huge thanks to our team,Physicians and patients. We are moving the conversation forward ! #proudtobeanteris #DurAVR
0
1
12
@HEARTinMagnet
Pankaj Garg
2 years
An insight into why aortic flow is becoming a novel therapeutic target. In collaboration with world experts in aortic physiology. @NatureNews @NatRevCardiol @Nature #WhyCMR #4DFlowCMR Thanks ALL (@chrismeduri) and legendary Michael Markl! Paper ⬇️ https://t.co/9AUHY3CZsw
5
33
100
@chrismeduri
Chris Meduri, MD MPH
2 years
DurAVR US EFS results presented @TCTMD by @azeemlatib today In small annuli patients (mean 22.2): ✔️ safe, easy to use ✔️ no pacemakers ✔️ 93% no/trace, 7% mild PVL 🎯mean EOA 2.36 🎯MPG 7.8 🎯DVI 0.71 This groundbreaking, first biomimetic valve will change AS treatment
3
16
71
@chrismeduri
Chris Meduri, MD MPH
2 years
It is with great pleasure to announce the completion of the DurAVR EFS enrollment! Thank you @umichCVC. This first-in-class biomimetic valve exceeded already remarkable prior results. More details next week in San Fran @TCTMD and in London as a LBCT @PCRonline. @AnterisTech #tavr
1
11
48
@chrismeduri
Chris Meduri, MD MPH
2 years
Congratulations to the incredible team @ClevelandClinic for 3 great DurAVR cases last week. All with excellent results! Always great seeing good friends Rishi Puri Amar Krishnaswamy @tavrkapadia and super fellow @Triplet_Trav ! Look forward to more soon! #tavr @PCRonline @TCTMD
0
9
47
@chrismeduri
Chris Meduri, MD MPH
2 years
Congratulations to @DrTomWaggoner and his team on 2 outstanding DurAVR cases this week. Seeing your team do a pristine case in only 20 minutes is a testament to your whole program! Look forward to many more soon. @AnterisTech
@DrTomWaggoner
Thomas Waggoner
2 years
Congrats to our phenomenal TMC SHD & CV Research Teams for implanting the first 2 DurAVR biomimetic TAVRs in ARIZONA, 2nd in the US! This could be transformative technology in the TAVR space. Will be very interesting to see how fast this potential disruptive advancement grows!
1
0
18
@chrismeduri
Chris Meduri, MD MPH
2 years
Incredibly work by @MonteHeart and proud of @AnterisTech to announce the first patients enrolled in the DurAVR US EFS study. The first US patients treated with a biomimetic valve! Incredible results, small annuli with mean EOA of 2.2 and mean gradient of 4 acutely! @azeemlatib
2
4
37
@chrismeduri
Chris Meduri, MD MPH
2 years
An incredible result for this patient from a remarkable team. Congrats Anita Asgar and team! More to come! @J_Sathananthan @JoaoLCavalcante @hahn_rt @modine_thomas @drnvanmieghem @AndreasRck2 @GilbertTangMD @DrTomWaggoner @GAilawadiMD @sellers_steph @azeemlatib @bapat_savrtavr
@AnterisTech
Anteris Technologies
2 years
#AnterisTech announces the first #ValveInValve procedure with #DurAVR™ THV has been completed by Dr. Anita Asgar in #Canada as part of Health Canada’s Special Access Program. $AVR #TAVR #TAVI #Innovation #ProudtobeAnteris Read the Full Announcement: https://t.co/xtojctWhqT
0
3
18
@chrismeduri
Chris Meduri, MD MPH
2 years
Great article by @michaelTCTMD on the impact/importance of no-implant shunts. RF allows for a durable septectomy.
@TCTMD
TCTMD
2 years
No-Implant Shunt for HF Looks Safe, Feasible in Early Snapshot https://t.co/DSL7yhsMwQ
0
3
6
@AnterisTech
Anteris Technologies
2 years
.@chrismeduri presents the latest data from the DurAVR™ THV FIH Study demonstrating sustained haemodynamic performance at 1 year. #TAVR $AVR #TAVI #cardiology #AnterisTech #TVT2023
0
3
21
@AnterisTech
Anteris Technologies
2 years
#Anteristech announces powerful new data from the DurAVR™ THV FIH Study demonstrating sustained haemodynamic performance at 1 year in 12 patients. #TAVR $AVR #TAVI #cardiology #AnterisTech Read Full Announcement: https://t.co/GdPXHMlr5r
1
13
37
@PCRonline
PCRonline 🫀
2 years
.@AnterisTech shares data from the DurAVR THV FIH study. It shows sustained haemodynamic performance at 1 year. Presented by @SusheelKodaliMD with simultaneous publication at #EuroPCR. #TAVR #TAVI Sponsored post by @AnterisTech
0
5
16
@GilbertTangMD
Dr. Gilbert Tang
2 years
@EuroInterventio
EuroIntervention
2 years
The DurAVR transcatheter heart valve was evaluated in a first-in-human study for treating symptomatic severe aortic stenosis. The study demonstrated a good safety profile and promising haemodynamic performance sustained at 1 year. #EAPCI #EUROPCR https://t.co/5d61YnqVwr
3
7
26